西格列汀联合二甲双胍治疗 2 型糖尿病的临床效果

目的 探讨西格列汀联合二甲双胍治疗2型糖尿病（T2DM）的临床效果及安全性。方法 收集2010年1月～2013年6月就诊于岳阳市第二医院的T2DM患者122例。将其分为三组：二甲双胍组（38例，二甲双胍0．5g，每天2次）、西格列汀组（42例，西格列汀100mg，每天1次）和联合用药组（42例，二甲双胍联合西格列汀）。12周后观察并比较三组间各项指标的变化。结果 治疗后二甲双胍组、西格列汀组与联合用药组体重指数、空腹血糖、餐后2h血糖、糖化血红蛋白（HbA1c）较治疗前均下降（均P〈0．05）。与二甲双胍组或西格列汀组单药治疗后比，联合用药组治疗后体重指数、空腹血糖、餐后2h血糖及HbA1c均显著下降（均P〈0．05）。结论 西格列汀治疗T2DM安全有效，进一步联合二甲双胍治疗，其疗效优于单用二甲双胍或西格列汀。

Clinical effect of Sitagliptin combined with Metformin in the treatment of patients with type 2 diabetes

Objective To investigate the efficacy and safety of Sitagliptin combined with Metformin in the treatment of type 2 diabetic patients. Methods 122 patients were recruited from the Second Hospital of Yueyang City from January 2010 to June 2013. All patients were divided into three groups： Mefformin group （38 patients, Metformin 0.5 g, bid）, Sitagliptin group （42 patients, Sitagliptin 100 mg, qd） and combined therapy group （42 patients, Mefformin and Sitagliptin）. The test indicators were recorded and compared among the three groups after 12 weeks. Results Body mass index, fasting blood-glucose, 2-hour postprandial blood glucose and HbA le after etreatment in the Metformin group, Sitagliptin group and combined therapy group were significantly decreased compared with those before treatment （all P 〈 0.05）. Compared with those in Metformin group or Sitagliptin group, body mass index, fasting blood-glucose, 2-hour postprandial blood glucose and HbA1c in combined therapy group were significantly decreased （all P 〈 0.05）. Conclusion Sitagliptin has efficacy and safety for the treatment of T2DM. Combined Sitagliptin with mefformin are more effective than Sitagliptin or mefformin alone in the treatment of T2DM.